Charting a path toward combination therapy for Alzheimer's disease

Diane Stephenson, Dan Perry, Cynthia Bens, Lisa J. Bain, Donald Berry, Michael Krams, Reisa Sperling, David Dilts, Johan Luthman, Debra Hanna, John McKew, Robert Temple, F. Owen Fields, Stephen Salloway, Russell Katz

Research output: Contribution to journalArticle

21 Citations (Scopus)

Abstract

It is acknowledged that progress in combined therapeutic approaches for Alzheimer's disease (AD) will require an unprecedented level of collaboration. At a meeting co-hosted by the Accelerate Cure/Treatments for Alzheimer's Disease Coalition and the Critical Path Institute, investigators from industry, academia and regulatory agencies agreed on the need for combinatorial approaches to treating AD. The need for advancing multiple targets includes recognition for novel adaptive trial designs that incorporate existing and new biomarkers to evaluate drug effects independently and in combination. A combination trial now being planned may test drugs targeting different pathogenic pathways or multiple targets along a common pathway. Collaborations and consortia-based strategies are pivotal for success and a regulatory framework is recommended for success.

Original languageEnglish (US)
Pages (from-to)107-113
Number of pages7
JournalExpert Review of Neurotherapeutics
Volume15
Issue number1
DOIs
StatePublished - Jan 1 2014

Fingerprint

Alzheimer Disease
Critical Pathways
Drug Delivery Systems
Industry
Therapeutics
Biomarkers
Research Personnel
Pharmaceutical Preparations

Keywords

  • Alzheimer's disease
  • Co-development
  • co-development
  • collaboration
  • combination therapy
  • novel therapy

ASJC Scopus subject areas

  • Clinical Neurology
  • Neuroscience(all)
  • Pharmacology (medical)

Cite this

Stephenson, D., Perry, D., Bens, C., Bain, L. J., Berry, D., Krams, M., ... Katz, R. (2014). Charting a path toward combination therapy for Alzheimer's disease. Expert Review of Neurotherapeutics, 15(1), 107-113. https://doi.org/10.1586/14737175.2015.995168

Charting a path toward combination therapy for Alzheimer's disease. / Stephenson, Diane; Perry, Dan; Bens, Cynthia; Bain, Lisa J.; Berry, Donald; Krams, Michael; Sperling, Reisa; Dilts, David; Luthman, Johan; Hanna, Debra; McKew, John; Temple, Robert; Fields, F. Owen; Salloway, Stephen; Katz, Russell.

In: Expert Review of Neurotherapeutics, Vol. 15, No. 1, 01.01.2014, p. 107-113.

Research output: Contribution to journalArticle

Stephenson, D, Perry, D, Bens, C, Bain, LJ, Berry, D, Krams, M, Sperling, R, Dilts, D, Luthman, J, Hanna, D, McKew, J, Temple, R, Fields, FO, Salloway, S & Katz, R 2014, 'Charting a path toward combination therapy for Alzheimer's disease', Expert Review of Neurotherapeutics, vol. 15, no. 1, pp. 107-113. https://doi.org/10.1586/14737175.2015.995168
Stephenson, Diane ; Perry, Dan ; Bens, Cynthia ; Bain, Lisa J. ; Berry, Donald ; Krams, Michael ; Sperling, Reisa ; Dilts, David ; Luthman, Johan ; Hanna, Debra ; McKew, John ; Temple, Robert ; Fields, F. Owen ; Salloway, Stephen ; Katz, Russell. / Charting a path toward combination therapy for Alzheimer's disease. In: Expert Review of Neurotherapeutics. 2014 ; Vol. 15, No. 1. pp. 107-113.
@article{0812c03d4dc742a095f6f5d343311084,
title = "Charting a path toward combination therapy for Alzheimer's disease",
abstract = "It is acknowledged that progress in combined therapeutic approaches for Alzheimer's disease (AD) will require an unprecedented level of collaboration. At a meeting co-hosted by the Accelerate Cure/Treatments for Alzheimer's Disease Coalition and the Critical Path Institute, investigators from industry, academia and regulatory agencies agreed on the need for combinatorial approaches to treating AD. The need for advancing multiple targets includes recognition for novel adaptive trial designs that incorporate existing and new biomarkers to evaluate drug effects independently and in combination. A combination trial now being planned may test drugs targeting different pathogenic pathways or multiple targets along a common pathway. Collaborations and consortia-based strategies are pivotal for success and a regulatory framework is recommended for success.",
keywords = "Alzheimer's disease, Co-development, co-development, collaboration, combination therapy, novel therapy",
author = "Diane Stephenson and Dan Perry and Cynthia Bens and Bain, {Lisa J.} and Donald Berry and Michael Krams and Reisa Sperling and David Dilts and Johan Luthman and Debra Hanna and John McKew and Robert Temple and Fields, {F. Owen} and Stephen Salloway and Russell Katz",
year = "2014",
month = "1",
day = "1",
doi = "10.1586/14737175.2015.995168",
language = "English (US)",
volume = "15",
pages = "107--113",
journal = "Expert Review of Neurotherapeutics",
issn = "1473-7175",
publisher = "Expert Reviews Ltd.",
number = "1",

}

TY - JOUR

T1 - Charting a path toward combination therapy for Alzheimer's disease

AU - Stephenson, Diane

AU - Perry, Dan

AU - Bens, Cynthia

AU - Bain, Lisa J.

AU - Berry, Donald

AU - Krams, Michael

AU - Sperling, Reisa

AU - Dilts, David

AU - Luthman, Johan

AU - Hanna, Debra

AU - McKew, John

AU - Temple, Robert

AU - Fields, F. Owen

AU - Salloway, Stephen

AU - Katz, Russell

PY - 2014/1/1

Y1 - 2014/1/1

N2 - It is acknowledged that progress in combined therapeutic approaches for Alzheimer's disease (AD) will require an unprecedented level of collaboration. At a meeting co-hosted by the Accelerate Cure/Treatments for Alzheimer's Disease Coalition and the Critical Path Institute, investigators from industry, academia and regulatory agencies agreed on the need for combinatorial approaches to treating AD. The need for advancing multiple targets includes recognition for novel adaptive trial designs that incorporate existing and new biomarkers to evaluate drug effects independently and in combination. A combination trial now being planned may test drugs targeting different pathogenic pathways or multiple targets along a common pathway. Collaborations and consortia-based strategies are pivotal for success and a regulatory framework is recommended for success.

AB - It is acknowledged that progress in combined therapeutic approaches for Alzheimer's disease (AD) will require an unprecedented level of collaboration. At a meeting co-hosted by the Accelerate Cure/Treatments for Alzheimer's Disease Coalition and the Critical Path Institute, investigators from industry, academia and regulatory agencies agreed on the need for combinatorial approaches to treating AD. The need for advancing multiple targets includes recognition for novel adaptive trial designs that incorporate existing and new biomarkers to evaluate drug effects independently and in combination. A combination trial now being planned may test drugs targeting different pathogenic pathways or multiple targets along a common pathway. Collaborations and consortia-based strategies are pivotal for success and a regulatory framework is recommended for success.

KW - Alzheimer's disease

KW - Co-development

KW - co-development

KW - collaboration

KW - combination therapy

KW - novel therapy

UR - http://www.scopus.com/inward/record.url?scp=84920834831&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84920834831&partnerID=8YFLogxK

U2 - 10.1586/14737175.2015.995168

DO - 10.1586/14737175.2015.995168

M3 - Article

C2 - 25540951

AN - SCOPUS:84920834831

VL - 15

SP - 107

EP - 113

JO - Expert Review of Neurotherapeutics

JF - Expert Review of Neurotherapeutics

SN - 1473-7175

IS - 1

ER -